Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC
March 10th 2023Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.
Read More